Kidney Cancer

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.

Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.

Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.

Early data suggest personalized neoantigen vaccines activate the immune system and sustain tumor control in some patients with kidney cancer.

June brought genitourinary cancer updates, and CURE is sharing the latest in kidney cancer treatment, as well as FDA approvals, cancer vaccines and more.

Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.

Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models.

A phase 1b study of HC-7366 plus Welireg for advanced clear cell renal cell carcinoma has completed the dose escalation portion of the clinical trial.

Dr. Susan Rux, a respected nursing leader and researcher, empowers teams, mentors future leaders, and advances inclusive clinical research in kidney cancer.

Living with stage 4 kidney cancer has taught me to embrace the present, cherish connection and find gratitude each day in unexpected places.

For the past 2 years, I have worked alongside Carmela Cuccurullo, NP.

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.

Following a social media takeover with CURE, Sid Sadler sat down to talk about the topic of Kidney Cancer Awareness Month and patient advocacy.

CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.

Sid Sadler discusses kidney cancer awareness, patient advocacy and the need for specialized care to improve access to treatments and clinical trials.

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.